Infex Therapeutics Holdings PLC
Registered name: INFEX THERAPEUTICS HOLDINGS PLC
Infex Therapeutics Holdings PLC made £0 revenue and a £17.5m loss in the year to 31 Jul 2025.
Infex Therapeutics Holdings PLC’s revenue was £0 in the year to 31 Jul 2025, with a loss of £17.5m and 0 employees. The company is classified under “activities of other holding companies” and is based in London; we hold 3 years of its filed accounts.
- Status
- Active
- Location
- London, London
- Age
- 4 yrs · since 2022
- Type
- Public Limited Company
Pass-through vehicle. This looks like a holding, staffing or umbrella company. Its revenue and profit may largely pass through to or from other entities, so the figures may not reflect a standalone operating business. It is excluded from our opportunity lists.
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “Mr J P Moulton has been registered at Companies House as the ultimate controlling party.”
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Jul 2023 | 31 Jul 2024 | 31 Jul 2025 |
|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L |
| Profit & loss | |||
| Revenue (turnover) | £0 | £0 | £0 |
| Operating profit | −£869k | −£1.4m | −£6.2m |
| Profit before tax | −£306k | −£419k | −£17.5m |
| Profit after tax | −£306k | −£419k | −£17.5m |
| Profit (best available) | −£306k | −£419k | −£17.5m |
| Employees (average) | 0 | 0 | 0 |
| Ratios | |||
| Profit margin | — | — | — |
| Balance sheet — indirect signals, not revenue | |||
| Cash at bank | £572k | £605k | £1.4m |
| Net assets | £2.7m | £2.6m | £1.8m |
| Current assets | £6.6m | £11m | £3.4m |
| Debtors | £6m | £10.4m | £1.9m |
| Cash from operations | £886k | £1.4m | — |
| Source | FullAccounts · bulk data Oct 2023 | FullAccounts · bulk data Dec 2024 | FullAccounts · bulk data Oct 2025 |
How the business works
- Profit margin
- —
- Profit ÷ revenue.
- Gross margin
- —
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- —
- Revenue ÷ average employees.
- Profit per employee
- —
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- —
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▼33%
- Now £1.8m
- Cash at bank
- ▲134%
- Now £1.4m
- Headcount
- —
- Now 0
- Deferred income
- —
- Now —
- Fixed assets
- —
- Now —
Group structure
Subsidiaries (1)
- Infex Therapeutics LimitedRev. — · Profit £8.2m
From the Persons with Significant Control register (corporate controllers only).
Sources
Latest figures from FullAccounts for the year to 31 Jul 2025 (profit −£17.5m), from the Companies House accounts bulk data published Oct 2025. Spotted an error? Request a correction.
Updated from Companies House on 15 Oct 2026
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.